An Open-Label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis.
Phase of Trial: Phase IV
Latest Information Update: 07 Oct 2009
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 18 Dec 2008 New trial record.